Interestingly, cases of renal failure with SGLT-2 inhibitors were four times more likely to report concomitant use of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and diuretics, compared to cases with SGLT-2 inhibitors reporting other adverse events [10]. This evidence concerns the gene SLC5A2 and Renal insufficiency.